← Back to Patent Explorer
US4352808A Expired / Lapsed US ⏱️ 0.0 years remaining

3-Aralkyloxy-2,3-dihydro-2-(imidazolylmethyl)benzo(b)thiophenes and related derivatives, their use as antimicrobials and pharmaceutical formulations useful therefore

Assignee: Merck Sharp & Dohme LLC
•
Filing: 1980-12-12
•
Granted: 1982-10-05
•
Expires: 2000-12-12
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract 3-Aralkyloxy-2,3-dihydro-2-(imidazolylmethyl(benzo(b)thiophenes and related derivatives having antifungal, antibacterial, and antiprotozoal activity are prepared by the reaction of the corresponding 2,3-dihydro-3-hydroxy-2-(imidazolylmethyl)benzo(b)thiophene or related derivative and an aralkyl halide. Preferred compounds are those where the aralkyl function is a hetercyclic aromatic, particularly 2-chloro-3-thenyl, and where the benzene nucleus is substituted by chlorine or fluorine. Pharmaceutical formulations comprising compounds of this invention are described, as well as the method for their use in treating microbial infections.

Inventors

  • 👤 Dinanath F. Rane
  • 👤 John J. Wright
  • 👤 Russell E. Pike

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 14:31
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/16; C07D295/18; C07D295/182; C07D295/185; A; A01; A01N; A01N43/00; A01N43/48; A01N43/50; A01N43/64; A01N43/647; A01N43/653; A61; A61P; A61P31/00; A61P31/04; A61P33/00; A61P33/02; C07D231/00; C07D231/02; C07D231/10; C07D231/12; C07D233/00; C07D233/54; C07D233/56; C07D249/00; C07D249/02; C07D249/08; C07D335/00; C07D335/04; C07D335/06

Claims Analysis

Total Claims: 25
Claim 1
Independent Claim 215 words
A compound selected from the group consisting of a compound defined by formula: ##STR4## wherein n is 0 to 4; p is 0 or 1; R and R 1 are independently H, lower alkyl, halogen, halogenated lower alkyl, nitro, or amino; X is oxygen, sulfur, sulfinyl, or sulfonyl; Y is imidazole, or lower alkyl and aryl derivatives of the foregoing, said aryl being a member selected from the group consisting of phenyl, halophenyl, and loweralkylphenyl; Z is a member selected from the group consisting of alkyl of 1 to 10 carbons, alkenyl of 3 to 10 carbons, alkynyl, of 3 to 10 carbons, cycloalkyl of 3 to 6 carbons, and heterocyclic aromatic groups selected from the group consisting of 2-thienyl, 3-thienyl, pyridyl, quinolyl, thiazolyl and furanyl, and the lower alkyl and halogen substituted derivatives thereof, provided that when n is 0, Z is not 1-alkynyl; and where n is 1 to 4, Z is also a member selected from the group consisting of phenyl, phenyl substituted by lower alkyl, halogen, or N-(N'-lower alkanoyl-piperazine), alkoxy of 1 to 10 carbons, alkylthio of 1 to 10 carbons, aryloxy, and arylthio, wherein said aryl moiety is a member selected from the group consisting of phenyl, halophenyl and lower alkyl phenyl; and the pharmaceutically acceptable acid addition salts thereof.
Claim 2
Dependent Claim 215 words
A compound selected from the group consisting of a compound defined by formula: ##STR4## wherein n is 0 to 4; p is 0 or 1; R and R 1 are independently H, lower alkyl, halogen, halogenated lower alkyl, nitro, or amino; X is oxygen, sulfur, sulfinyl, or sulfonyl; Y is imidazole, or lower alkyl and aryl derivatives of the foregoing, said aryl being a member selected from the group consisting of phenyl, halophenyl, and loweralkylphenyl; Z is a member selected from the group consisting of alkyl of 1 to 10 carbons, alkenyl of 3 to 10 carbons, alkynyl, of 3 to 10 carbons, cycloalkyl of 3 to 6 carbons, and heterocyclic aromatic groups selected from the group consisting of 2-thienyl, 3-thienyl, pyridyl, quinolyl, thiazolyl and furanyl, and the lower alkyl and halogen substituted derivatives thereof, provided that when n is 0, Z is not 1-alkynyl; and where n is 1 to 4, Z is also a member selected from the group consisting of phenyl, phenyl substituted by lower alkyl, halogen, or N-(N'-lower alkanoyl-piperazine), alkoxy of 1 to 10 carbons, alkylthio of 1 to 10 carbons, aryloxy, and arylthio, wherein said aryl moiety is a member selected from the group consisting of phenyl, halophenyl and lower alkyl phenyl; and the pharmaceutically acceptable acid addition salts thereof.
Claim 3
Dependent Claim 9 words
A compound of claim 1 wherein X is S.
Claim 4
Dependent Claim 9 words
A compound of claim 1 wherein p is 0.
Claim 5
Dependent Claim 9 words
A compound of claim 1 wherein Y is imidazole.
Claim 6
Dependent Claim 12 words
A compound of claim 1 wherein Z is a heterocyclic aromatic group.
Claim 7
Dependent Claim 9 words
A compound of claim 2 wherein p is 0.
Claim 8
Dependent Claim 13 words
A compound of claim 2 wherein p is 0 and Y is imidazole.
Claim 9
Dependent Claim 34 words
The cis-isomer of a compound of claim 2 wherein p is 0 and Y is imidazole, having the formula: ##STR5## wherein R, R 1 , Z and n are as defined in claim 1.
Claim 10
Dependent Claim 12 words
A compound of claim 8 wherein Z is a heterocyclic aromatic group.
Claim 11
Dependent Claim 24 words
A compound of claim 8 wherein R is H, R 1 is 6-chloro, n is 1, and Z is 2-chloro-3-thienyl, said compound being cis-6-chloro-3-(2'-chloro-3'-thenyloxy)-2,3-dihydro-2-(1"-imidazolylmethyl)benzo(b)thiophene.
Claim 12
Dependent Claim 24 words
A compound of claim 8 wherein R is H, R 1 is 6-chloro, n is 1, and Z is 3-thienyl, said compound being cis-6-chloro-3-(3'-thenyloxy)-2,3-dihydro-2-(1"-imidazolylmethyl)benzo(b)thiophene.
Claim 13
Dependent Claim 24 words
A compound of claim 8 wherein R is H, R 1 is 6-fluoro, n is 1 and Z is 2-chloro-3-thienyl, said compound being cis-6-fluoro-3-(2'-chloro-3'-thenyloxy)-2,3-dihydro-2-(1"-imidazolylmethyl)benzo(b)thiophene.
Claim 14
Dependent Claim 24 words
A compound of claim 8 wherein R is H, R 1 is 5-fluoro, n is 1, and Z is 2-chloro-3-thienyl, said compound being cis-5-fluoro-3-(2'-chloro-3'-thenyloxy)-2,3-dihydro-2-(1"-imidazolylmethyl)benzo(b)thiophene.
Claim 15
Dependent Claim 12 words
A compound of claim 8 where n is 1, Z is ##STR6##
Claim 16
Dependent Claim 32 words
A composition useful for inhibiting the growth of fungi, bacteria or protozoa which comprises an antifungally, antibacterially, or antiprotozoally effective amount of a compound of claim 1 in admixture with a carrier.
Claim 17
Dependent Claim 18 words
The composition of claim 15 suitable for pharmaceutical use wherein the carrier is a pharmaceutically acceptable, non-toxic carrier.
Claim 18
Dependent Claim 27 words
The composition of claim 16 which comprises an antifungally, antibaterially, or antiprotozoally effective amount of the compound of claim 8 together with a pharmaceutically acceptable non-toxic carrier.
Claim 19
Dependent Claim 25 words
The composition of claim 17 which comprises an antifungally effective amount of the compound of claim 8 together with a pharmaceutically acceptable non-toxic topical carrier.
Claim 20
Dependent Claim 27 words
The composition of claim 18 which comprises an antifungally effective amount of the compound of claim 8 together with a pharmaceutically acceptable non-toxic oral or parenteral carrier.
Claim 21
Dependent Claim 41 words
A method of inhibiting the growth of fungi, bacteria, or protozoa which comprises subjecting a host object containing or subject to attack by fungi, bacteria, or protozoa to an antifungally, antibacterially, or antiprotozoally effective amount of a compound of claim 1.
Claim 22
Dependent Claim 11 words
The method of claim 20 wherein the compound is administered topically.
Claim 23
Dependent Claim 31 words
The method of claim 20 which comprises administering to the host an antifungally, antibacterially, or antiprotozoally effective amount of the compound of claim 8 together with a pharmaceutically acceptable non-toxic carrier.
Claim 24
Dependent Claim 24 words
The method of claim 22 which comprises administering an antifungally effective amount of a compound of claim 8 wherein the compound is administered topically.
Claim 25
Dependent Claim 26 words
The method of claim 22 which comprises administering an antifungally effective amount of a compound of claim 8 wherein the compound is administered orally or parenterally.

References Cited (Backward Citations)

GB1445707A Cited
US3927018A Cited
US4036970A Cited
US4078071A Cited
US4269845A Cited
US4267179A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-10-04 1986-04-05 1986-10-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-10-04 1990-04-05 1990-10-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-10-04 1994-04-05 1994-10-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag